Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine’s Crenessity
The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s antibody expertise, transfer the global rights outside of China for a corticotropin-releasing hormone therapy to an unnamed “business partner.”
The deal will see HBM Alpha Therapeutics, which was formed around Harbour’s antibody expertise, transfer the global rights outside of China for a corticotropin-releasing hormone therapy to an unnamed “business partner.”
